FDA Issues Model-Based Drug Development Guidelines
Published Date: 6/3/2026
Notice
Summary
The FDA just released new guidance to help drug makers use smart computer models to develop medicines faster and safer. This update sets clear rules on how to plan, check, and share model-based evidence, making drug development smoother for companies worldwide. Starting now, drug developers should follow these guidelines to save time and money while working with regulators.
No Economic Impacts Identified for this Document
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11062 — Elite Laboratories, Inc. et al.; Withdrawal of Approval of 16 Abbreviated New Drug Applications
The FDA is officially pulling the plug on 16 generic drug approvals because the companies told them these medicines aren’t being sold anymore. This change kicks in on July 6, 2026, and it won’t stop companies from trying again later if they want. If you’re a drug maker or just curious, this means fewer old approvals cluttering the books and a cleaner, fresher drug list.
2026-11060 — Drug and Device Manufacturer Communications With Payors, Formulary Committees, and Similar Entities-Questions and Answers; Revised Draft Guidance for Industry; Availability
The FDA just released a revised draft guide to help drug and device makers share important cost and coverage info with insurance companies and similar groups. This update clears up how to talk about approved products, unapproved products, and new uses, making it easier for everyone to understand the rules. Companies should send their feedback by August 3, 2026, so the FDA can finalize the guide—potentially speeding up coverage decisions and saving money.
2026-11054 — Leveraging Prior Knowledge in the Development of Human Gene Therapy Products Incorporating Genome Editing; Draft Guidance for Industry; Availability
The FDA just dropped a draft guide to help companies making gene therapy products that use genome editing. It shows how to use what’s already known to speed up development and get safer, smarter treatments to patients faster. If you’re in this field, send your feedback by September 1, 2026, so your voice shapes the final rules—saving time and money down the road!
2026-11101 — Third Annual Animal Drug User Fee Educational Conference; Public Meeting
The FDA is hosting its Third Annual Animal Drug User Fee Educational Conference on July 7, 2026, to help drug makers and animal health experts understand the new animal drug approval process. This free event is both in-person and online, making it easy to join. Stakeholders should register early and can send feedback within 90 days after the meeting to help shape future policies and fees.
2026-10908 — Medical Devices; General Hospital and Personal Use Devices; Classification of the Rigid Sterilization Container With Electronic Monitoring
The FDA is officially classifying rigid sterilization containers with electronic monitoring as Class II devices, meaning they have special safety rules but fewer hurdles than the strictest category. This change helps hospitals and medical device makers get these safer, smarter containers to patients faster and easier. The new rules took effect June 1, 2026, making it simpler and potentially less costly to bring these devices to market.
2026-10904 — Medical Devices; Gastroenterology-Urology Devices; Classification of the Orally Ingested Transient Device for Constipation
The FDA is officially putting the new swallowed device for constipation into a safer, easier-to-manage category called Class II. This change helps make sure the device works well and is safe, while also speeding up patient access to this cool innovation by cutting down red tape. The new rules took effect June 1, 2026, and could save companies time and money getting their devices approved.
Previous / Next Documents
Previous: 2026-11111 — Agency Information Collection Activities; Submission to the Office of Management and Budget for Review and Approval; Comment Request; Generic Clearance for the Collection of Qualitative Feedback on National Security and Emergency Preparedness Communications (NSEPC)
The Cybersecurity and Infrastructure Security Agency (CISA) is asking for public feedback on how they collect opinions about national security and emergency messages. This helps make sure their communications are clear and useful without causing extra hassle. Comments are open until July 6, 2026, and no costs or big changes are expected.
Next: 2026-11113 — Tuna Tariff-Rate Quota for Calendar Year 2026 for Tuna Classifiable Under Subheading 1604.14.22, Harmonized Tariff Schedule of the United States (HTSUS)
In 2026, the U.S. will allow up to 16.36 million kilograms of tuna in airtight containers to enter with a lower 6% tariff. If imports go over that amount, a higher 12.5% tariff kicks in. This affects tuna importers who need to watch their shipments from January 1 to December 31, 2026, to avoid extra costs.